首页> 中文期刊> 《中国实用医刊》 >诱导化疗期间行微小残留白血病检测在急性髓系白血病预后判断中的价值

诱导化疗期间行微小残留白血病检测在急性髓系白血病预后判断中的价值

摘要

Objective To analyze the relationship between minimal residual disease(MRD)de-tection in AML patients on seventh day of induction chemotherapy and prognosis. Methods The MRD was detected by multi-parameter flow cytometry in 45 cases of primary,newly diagnosed adult AML on seventh day of remission induction chemotherapy. Results Complete remission(CR)rate after the first course in MRD < 10-2 group was significantly higher than that in MRD > 10-2 group( 85. 7% and 58. 3% ,respectively,P < 0. 05,the difference had statistically significance);For patients in MRD > 10-2 group,prolonged the chemotherapy course for a few more days could improve the CR rate(remission rates were 66. 7% and 55. 6% ,but the difference was not statistically significant(,P > 0. 05). Conclu-sions Detection of MRD on seventh day of remission induction chemotherapy in AML is helpful in pre-dicting the prognosis,as well as providing the basis for prolonging chemotherapy.%目的:分析急性髓系白血病(AML)患者诱导缓解化疗第7天微小残留白血病(MRD)检测与预后的关系。方法采用多参数流式细胞分析术对45例原发、初治成人 AML 患者于诱导缓解化疗第7天行 MRD 检测。结果化疗第7天 MRD <10-2患者1个疗程完全缓解(CR)率明显高于 MRD >10-2组患者(分别为85.7%和58.3%,P <0.05,差异有统计学意义);对于化疗第7天 MRD >10-2者,适当延长化疗时间可提高1个疗程 CR 率(缓解率分别为66.7%和55.6%),但两者相比差异无统计学意义(P >0.05)。结论于诱导缓解化疗第7天行MRD 检测有助于 AML 预后的评估,同时为是否延长化疗时间提供依据。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号